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ABSTRACT 
The cost effectiveness of antimicrobial stewardship (AMS) programmes was 
reviewed in hospital settings of Organisation for Economic Co-operation and 
Development (OECD) countries, and limited to adult patient populations. In each of 
the 36 studies, the type of AMS strategy and the clinical and cost outcomes were 
evaluated. The main AMS strategy implemented was prospective audit with 
intervention and feedback (PAIF), followed by the use of rapid technology, including 
rapid polymerase chain reaction (PCR)-based methods and matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) technology, for the treatment of 
bloodstream infections. All but one of the 36 studies reported that AMS resulted in a 
reduction in pharmacy expenditure. Among 27 studies measuring changes to health 
outcomes, either no change was reported post-AMS, or the additional benefits 
achieved from these outcomes were not quantified. Only two studies performed a full 
economic evaluation: one on a PAIF-based AMS intervention; and the other on use 
of rapid technology for the selection of appropriate treatment for serious 
Staphylococcus aureus infections. Both studies found the interventions to be cost 
effective. AMS programmes achieved a reduction in pharmacy expenditure, but there 
was a lack of consistency in the reported cost outcomes making it difficult to 
compare between interventions. A failure to capture complete costs in terms of 
resource use makes it difficult to determine the true cost of these interventions. 
There is an urgent need for full economic evaluations that compare relative changes 
both in clinical and cost outcomes to enable identification of the most cost-effective 
AMS strategies in hospitals. 
  
1. Introduction 
Use of antimicrobial agents to both treat and prevent infections is an essential 
component of medical care. Indeed, many advances in critical care medicine, 
surgery and transplantation would not be possible without the use of effective 
antimicrobials. Whilst antimicrobials benefit the individual patient, the emergence of 
resistance has consequences to all of society. In 2014, the World Health 
Organization (WHO) urged all countries to work together to improve surveillance and 
to address the issue of antimicrobial resistance 
(http://www.who.int/drugresistance/documents/surveillancereport/en). 
 
An effective approach to improving antimicrobial use in hospitals may be achieved 
by an organised antimicrobial management programme known as antimicrobial 
stewardship (AMS). The overarching goals of an AMS programme are to optimise 
clinical outcomes while minimising unintended consequences of antimicrobial use, 
including toxicity, the selection of opportunistic pathogens (such as Clostridium 
difficile) and the emergence of antimicrobial resistance [1]. AMS interventions have 
been reported to reduce antimicrobial consumption by 22–36% and lead to a cost 
reduction of US$200 000–900 000 per annum in some hospitals in the USA [2]. 
Despite this, it has been reported that it is difficult to attract adequate support for 
these activities as AMS is competing for resources against many other healthcare 
initiatives. 
 
Whilst there are many combinations of strategies available for the development of an 
AMS programme, it is unclear which are optimal. In evaluating the cost effectiveness 
of AMS interventions, all relevant changes to costs as well as health benefits 
achieved must be quantified and compared in order to understand whether the 
intervention offers value for money. Whilst there have been some studies that have 
reported AMS results in cost savings in terms of reducing drug acquisition costs, 
these do not include costs of AMS staff and other implementation activities, thus they 
may underestimate the cost of the intervention [3–10]. It is not clear whether the cost 
effectiveness of these programmes has been assessed fully. Such information is 
essential for making credible arguments to decision-makers about the value of 
funding these programmes. 
 
The aim of this structured review was to synthesise the existing literature on the cost 
effectiveness of AMS programmes. We report the cost and health outcomes 
assessed, the economic evaluation methods used and the overall findings of this 
body of research, including important knowledge gaps in this area. 
 
2. Methods 
2.1. Literature search 
A search for economic evaluations of AMS interventions was undertaken in the 
databases Embase, PubMed, Scopus, Web of Science, ProQuest, CINAHL and 
EconLit up to June 2014. Search terms used included the Mesh term ‘Anti Infective’ 
in conjunction with Stewardship, and search terms ‘Antimicrobial Stewardship’ AND 
‘cost*’; ‘Antimicrobial Stewardship’ AND ‘cost effectiveness’; and ‘Antimicrobial 
Stewardship’ AND ‘economic*’. 
 
2.2. Inclusion and exclusion criteria 
The inclusion criteria for critical assessment of studies on AMS cost effectiveness 
were: AMS intervention; cost-effectiveness analyses (CEAs) and cost analyses; 
based on adult inpatient population; AMS strategy clearly defined; and language 
restricted to English (Fig. 1). The exclusion criteria were: reviews; editorials; letter; 
commentaries; conference reports; and an AMS programme performed in a country 
that did not belong to the Organisation for Economic Co-operation and Development 
(OECD). 
 
Duplicates, reviews, editorials, conference reports, commentaries and studies from 
non-OECD countries were removed (Fig. 1). This was done so that only countries 
with similar economic capacities would be compared. The following information was 
extracted from the remaining studies: a clear definition of AMS strategies; costs; 
outcomes; and the perspective of the economic analysis. Only studies that included 
cost data relating to AMS initiatives were reviewed in further detail. For studies that 
reported a full CEA or a cost-utility analysis, a specifically designed data extraction 
tool was used based on the Drummond [11] checklist for CEAs. Studies were 
evaluated by one author (SC) under the guidance of KH. 
 
3. Results 
The final review included 36 studies [3–6,8–10,12–40] conducted in the USA (22), 
UK (2), Canada (2), France (2), Spain (2) Japan (2), Israel (1), Slovenia (1), Belgium 
(1) and Germany (1). The most common AMS strategy implemented was 
prospective audit with intervention and feedback (PAIF), followed by rapid 
technology such as rapid PCR-based methods, matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) technology, peptide nucleic acid 
probes for fluorescence in situ hybridisation (PNA FISH) and Etest strips, for the 
detection of minimum inhibitory concentrations of various antimicrobials for the 
treatment of bloodstream infections (BSIs). Specifically, the types of AMS strategies 
evaluated were: PAIF (18), rapid technology (6), antifungal stewardship (4), 
intravenous-to-oral (i.v.-to-p.o.) conversion (4), formulary restriction plus PAIF (2), 
rapid technology plus antifungal stewardship (1), and PAIF plus i.v.-to-p.o. 
conversion (1). 
 
Of the 36 included studies, 2 were full CEAs [13,14]; 27 studies reported changes to 
costs and health outcomes separately [3,5,8–10,12–14,22–40] and 9 reported only 
changes to costs [4,6,15–21]. Table 1 presents the methods and results for studies 
that measured only cost outcomes and Table 2 presents the methods and findings of 
those studies that measured both a clinical as well as a cost outcome. 
 
3.1. Costing studies that did not measure clinical outcomes 
Table 1 groups 9 of the 36 included studies that measured only the cost impact of 
AMS strategies [4,6,15–21]. PAIF was the most commonly evaluated strategy in this 
group (5/9; 56%) [4,6,15–17]; 2 studies focused on i.v.-to-p.o. conversion as a 
strategy [18,19]and 2 studies evaluated antifungal stewardship [20,21]. All nine 
studies reported a reduction in costs related to antimicrobial use as a result of 
implementing the AMS strategy. 
 
Five of the nine studies assessed reduction in total antibiotic expenditure (TAE) as a 
measure of success of the AMS strategy [4,15,16,18,20]. One of the remaining four 
studies expressed the cost savings as TAE per patient-day (PD) [17], the second as 
TAE per 1000 PDs [6], the third as TAE per patient [21] and the final study as mean 
additional cost per patient [19]. 
 
3.2. Cost consequence studies that measured clinical outcomes 
Table 2 groups the 27 studies that evaluated a change in cost as well as clinical 
outcome as a result of implementing an AMS strategy [3,5,8–10,12–14,22–40]. 
Thirteen (48.1%) of the studies measured cost savings as only TAE 
[3,5,8,10,22,23,25,26,28–32], one (4%) as TAE per admission [24], one (4%) as TAE 
per 1000 PDs [27], and finally one (4%) as TAE per PD [9] as a measure of success 
of the AMS strategy. One study [25] reported a loss of $215.99 due to 
implementation of the AMS strategy assessed. No pre-intervention data were 
included in this study and the loss recorded was due to the difference between 
prescribed and pharmacy-recommended antimicrobials. Of the studies that reported 
cost savings due to total antimicrobial expenditure, the range of savings was from 
$22 433.99 [31] to $4 314 664 [18] (adjusted to 2014 US$). Two further studies 
reported significant cost savings due to only antifungal stewardship interventions of 
$257 507.94 [9] and $399 841.83 [32], respectively. 
 
Five studies included cost savings in terms of length of stay (LOS) [5,10,35,36,39]; 
these cost savings ranged from $20 365.45 to $4 228 370.72 (adjusted to 2014 
US$). Four studies recorded cost savings in terms of reduced healthcare costs 
owing to more appropriate treatment of infections. Two studies compared different 
approaches of AMS: one study found no difference in costs [33]; whilst the second 
study recorded cost savings when a more active approach was used [34]. One study 
performed an economic analysis and found rapid technology to be cost effective in 
monetary terms only [40], and two further studies performed CEAs including a 
measure for health benefits gained by two different approaches [13,14]. 
 
PAIF was the most commonly evaluated strategy (12/27; 44%) [3,8,10,13,22–28,30]. 
In these 12 studies, the clinical outcomes measured ranged from LOS (6/12), 
mortality (6/12), presence of multiresistant organisms (3/12), C. difficile infection 
(CDI) rates (5/12) and 30-day re-admission rates (1/12). Of the 12 studies, 8 were 
from the USA, 2 from Japan and 1 each were from Israel and Canada. Eleven of the 
twelve studies reported a reduction in TAE and cost savings [3,8,10,13,22–24,26–
28,30], but one reported a loss of $215.99 [25]. One study also noted cost savings 
associated with the reduction in LOS [10]. Ten of the twelve studies reported the 
TAE [3,8,10,22,23,25,26,28-30], whilst one study reported TAE per admission [24] 
and one reported findings as TAE per 1000 PDs [27]. One study also specifically 
mentioned that a saving of $194 160 [3] was achieved by i.v.-to-p.o. conversion as 
one of the strategies included as well as PAIF in just 1 year of the programme. 
 
The second most common strategy evaluated in these 27 studies was rapid 
technology (7; 26%) [12,35–40]. All studies evaluated the impact of rapid technology 
in terms of rapid PCR [35,39,40], MALDI-TOF technology [36,38], PNA FISH [37,38] 
and Etest strips [12] for rapid results for the change to more appropriate 
antimicrobials for the treatment of BSIs. These studies took into account the cost to 
the hospital of the treatment of specific infections such as meticillin-resistant 
Staphylococcus aureus (MRSA), Candida and infections due to Gram-negative 
organisms in BSIs. Six of these seven studies were performed in the USA and one in 
Spain. Four of the seven studies included LOS as clinical outcome [35–37,39] and 
three reported a reduction and associated savings due to this [35,36,39]. One found 
no significant change in LOS [37]. Two studies evaluated the impact on the 
management of BSI and the outcomes of these clinical conditions [12,38], and one 
other evaluated the outcome of MRSA and meticillin-susceptible S. aureus (MSSA) 
infections with the use of rapid technology [40]. 
 
Of the remaining eight studies, two evaluated the impact of antifungal stewardship 
[9,32] and looked at LOS, mortality, re-admission rates and CDI, and one of them 
found a significant reduction in CDI rates and no change in the other parameters, but 
significant cost savings due to reduced antimicrobial utilisation [9]. Two further 
studies evaluated the impact of i.v.-to-p.o. conversion [5,31]; both studies were 
performed in the UK and measured LOS as a clinical outcome. Both studies reported 
a reduction in TAE and significant associated cost savings due to this reduction. One 
of the two studies reported a reduction in LOS and included the cost savings due to 
this. The second study [31] noted no change to the LOS in their setting. Two studies 
compared different AMS strategies with one another [33,34] and found that a more 
interactive approach resulted in better outcomes and that pharmacist-driven AMS 
was more effective than strategies adopting infectious diseases fellows. 
 
3.3. Cost-effectiveness analyses 
Only two studies performed a full CEA [13,14] and quantified the relative changes in 
costs and health gains due to AMS strategies, allowing an estimate of whether the 
strategy is value for money. Both evaluations used a US hospital context, although 
Brown and Paladino [14] also undertook an analysis for a European Union (EU) 
hospital context. Both CEAs used a hospital perspective and did not evaluate 
changes in societal costs as a result of the AMS programmes. Both of these 
interventions were found to be cost effective. 
 
The CEA by Scheetz et al. [13] used a decision analytic model with a decision tree 
depicting the clinical pathways followed by patients with BSIs. The aim of the study 
was to determine the cost effectiveness of AMS teams on the reduction of morbidity 
and mortality associated with nosocomial bacteraemia. 
 
The model is based on the assumption that an AMS programme can improve the 
clinical outcomes in patients with BSIs. The structure described was based on the 
outcomes of BSIs in the adult patient cohort at a large academic medical centre in 
the USA. The study used data from the literature as well as local cost information 
from the relevant healthcare environment to inform the model. This study found that 
an AMS team informing the most appropriate antibiotics to treat BSIs provided 
improved clinical outcomes in terms of reduced hospital stay and mortality. They also 
found that in their setting a clinical decision support system used to triage cases for 
specific attention was also found to be cost effective. The AMS programme was cost 
effective at US$2367 per quality-adjusted life-year (QALY) gained and the addition of 
a clinical decision support system was cost effective at US$481–36 319 per QALY. 
 
A second US study also used a decision analytic model with a decision tree to 
assess the cost effectiveness of novel technology based on rapid PCR testing in the 
microbiology laboratory compared with traditional empirical therapy [14]. The study 
found the implementation of rapid testing to inform the most appropriate selection of 
antibiotic for the treatment of infections with MRSA and MSSA resulted in improved 
outcomes for patients [14]. This study used data derived from the literature both from 
the EU and the USA to inform the model. Results showed that rapid PCR testing for 
MRSA reduced mortality rates while being less costly than empirical therapy in the 
EU and the USA across a wide range of MRSA prevalence rates and PCR test 
costs. In the EU, the cost-effectiveness ratios for empirical vancomycin and penicillin 
for the treatment of patients were €695 and €687 per life-year saved, respectively, 
compared with €636 per life-year saved for rapid PCR testing. In the USA, the cost-
effectiveness ratio was US$898 per life-year saved for empirical vancomycin and 
US$820 per life-year saved for rapid PCR testing 
 
Both studies were well designed and aligned with the recommendations by 
Drummond et al. [11] for the structure of CEAs. They provide useful information on 
the value for money of strategies to improve the quality of prescribing in hospitals. 
Also, one in particular [14] provided information on the cost effectiveness of rapid 
technology to assist in the timely selection of appropriate antimicrobials in the more 
effective treatment of BSI. However, both studies used published estimates rather 
than local primary data, a narrow economic perspective (i.e. hospitals), and a short 
time horizon for the evaluation. 
 
4. Discussion 
The majority of existing work evaluating AMS programmes has focused on clinical 
effectiveness. However, in the current economic climate, governments need to 
identify the optimal allocation of health resources to maximise health outcomes. A 
well performed CEA can provide valuable information on the gains in health relative 
to the cost of different health interventions. This will enable comparisons to be made 
to assess the value for money of strategies that are implemented. CEAs are 
currently being used in many countries for decision-making in health resource 
allocation [41]. The lack of cost-effectiveness studies for AMS programmes has been 
highlighted in a recent update to a Cochrane review on interventions to improve 
antibiotic prescribing practices for hospital inpatients [42]. 
 
AMS programmes are greatly varied in content owing to healthcare institutions 
having a range of patient demographics, resource availability, size and access to 
specialist services. This is demonstrated by the wide variety of AMS strategies 
evaluated by the studies included in this review. It may be that AMS is not a ‘one-
size-fits-all’ approach and programmes need to be tailored to the local context. A 
standardised approach to the collection of clinical and cost outcome data will allow 
comparison of the different approaches (two papers suggested a scoring system to 
rate AMS programmes). 
 
The lack of consistency in cost outcomes reported, evaluation perspectives taken, 
and availability of full economic evaluations that compare relative changes both in 
costs and health outcomes currently inhibits these comparisons and identification of 
efficient AMS strategies. More economic evaluations undertaken using a 
standardised approach to the evaluation and collection of relevant information to 
inform it are required to assess these interventions. 
 
The 36 studies included in this review all reported on the cost outcomes of the AMS 
strategies implemented in their specific institution. They all reported a decrease in 
cost after the introduction of AMS strategies, except for one study by Ijo and 
Feyerharm [25] that reported an overall loss of US$192. In all studies the costs were 
reported in multiple formats, including TAE as well as TAE per admission, per PD 
and per 1000 PDs. Antibiotic consumption was also reported in a few different 
formats, as days of therapy as well as defined daily doses (DDD) per 100 PDs and 
per 1000 PDs. Consistency in these parameter such as the WHO-recommended 
reporting would be useful when comparing the success of different strategies. 
 
Of the 36 studies, 24 studies reported on cost savings associated with reduced 
antimicrobial utilisation. The others included a broader range of cost savings, 
including hospital and rapid technology costs. 
 
In the studies evaluated in this review, 27 studies measured some clinical outcome 
as well as the cost savings associated with the intervention. The problem with only 
reporting cost savings, particularly when the focus is solely on reduced antimicrobial 
utilisation, is that this can be a misleading parameter to use to assess the success of 
AMS programmes, as reducing antimicrobial usage may not necessarily translate to 
improved clinical outcomes for patients. Even where studies have measured both 
clinical and cost outcomes, they are often reported separately and do not look at the 
relative change in both these outcomes, which would be important to assess the true 
value for money of the programme. 
 
Only 2 of the 36 studies evaluated the cost effectiveness of two AMS strategies. 
Both CEAs found that the strategies were cost effective using commonly used 
willingness-to-pay thresholds. However, both used a narrow hospital perspective and 
short timeframe for evaluations and as such may not have captured all costs and 
benefits to AMS programmes. If a societal perspective was adopted, the benefits of 
the intervention would have been far greater as the costs of antimicrobial resistance 
need to be assessed over a longer period of time. They were also both undertaken in 
a US context, which may limit generalisability, although one study also evaluated the 
AMS strategy in an EU context and reached the same conclusions, providing support 
that the findings are likely to be broadly generalisable. Both studies also used data 
from the literature to populate their models and did not use raw data to generate the 
situation at each individual healthcare setting. This might be a design issue as the 
data collected may not be maximally accurate for the purposes of the new analysis 
and therefore may not be a true reflection of what is occurring at that specific 
healthcare setting. The more accurate the parameters that can be used to analyse a 
strategy in an economic model, the less uncertainty will be associated with the final 
result. 
 
Other forms and variants of AMS programmes have not been subject to a full 
economic evaluation and have not been compared with one another, but compared 
only with a situation of no AMS. This means that although AMS programmes appear 
cost effective, it is not possible to compare between strategies to identify the most 
efficient strategy for a given setting. This is particularly problematic in the case of 
rapid technology. Rapid technology as a strategy in AMS has featured in many 
studies and they have concluded that the overall cost savings achieved were greater 
than the cost of the technology utilised. However, some of these technologies, such 
as MALDI-TOF, require significant monetary investment in set up and maintenance 
costs and no economic analyses have been performed to conclude whether these 
technologies are indeed cost effective. Further research is required to assess 
whether investment in these rapid technologies, in addition to less resource intensive 
AMS programmes, is justified. 
 
It is clear from the evidence presented in this review that AMS strategies can reduce 
antimicrobial costs and a broader range of hospital costs. Existing evidence also 
shows that rapid technology in conjunction with AMS programmes can improve 
patient outcomes by reducing the length of time patients are in hospital [36]. 
However, to identify the AMS programmes that offer the best value for money in a 
healthcare system that is facing ever-increasing resource constraints, there is an 
urgent need for more evidence on the cost effectiveness of these programmes. It is 
also important to note that the studies so far have not included the costs related to 
the reduction or delayed emergence of resistance, as recommended by Coast et al. 
[43]. Future economic evaluations need to accommodate these costs where 
possible. 
 
AMS programmes achieved a reduction in pharmacy expenditure, but a lack of 
consistency in cost outcomes was reported. A failure to capture other shifts in 
resource use that result from their introduction makes it difficult to determine the true 
cost of these interventions. There is an urgent need for full economic evaluations 
that compare relative changes both in clinical and cost outcomes to enable 
identification of the most cost-effective AMS strategies in hospitals. 
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